started · updated
PROTEXI Cancer Vaccine Platform Moves Toward First‑in‑Human Trials
Scientists from Celloram Inc., University Hospitals and Case Western Reserve University in Cleveland have created PROTEXI, a dendritic‑cell cancer vaccine that repurposes the massive SARS‑CoV‑2 immune memory generated by infection and vaccination. The platform pairs tumor‑specific antigens with spike‑protein epitopes to harness pre‑existing antiviral CD4+ helper T‑cell memory, boosting CD8+ cytotoxic responses.
In multiple preclinical mouse models of melanoma and breast cancer, PROTEXI slowed tumor growth, improved survival and converted immune‑cold tumors into ones that could be recognized and attacked. Efficacy was also shown in humanized mice using immune cells from COVID‑19‑vaccinated donors. The research was published in Nature Communications on 27 July 2026 and was funded by the Case Comprehensive Cancer Center and the U.S. National Cancer Institute. The team now plans first‑in‑human clinical trials of PROTEXI in patients with sarcoma.
Entities
Case Western Reserve University · Celloram Inc. · PROTEXI · PROTEXI · SARS‑CoV‑2 · SARS‑CoV‑2 spike protein · Seong‑Jin Kim · University Hospitals
Claims
What the coverage asserts, and how many sources carry each claim.
- [○ 1 SOURCE] PROTEXI synergizes with other immunotherapies to further reduce tumor burden. www.azolifesciences.com
- [● 5 SOURCES] PROTEXI leverages pre‑existing antiviral immune memory from SARS‑CoV‑2 infection or vaccination. www.diariodesalud.com.do · www.azolifesciences.com · science20.com · conowego.pl · www.globenewswire.com
- [● 5 SOURCES] Scientists from Celloram Inc., University Hospitals, and Case Western Reserve University developed the PROTEXI dendritic‑cell cancer vaccine platform. www.diariodesalud.com.do · www.azolifesciences.com · science20.com · www.globenewswire.com · conowego.pl
- [● 5 SOURCES] In preclinical mouse models of melanoma and breast cancer, PROTEXI slowed tumor growth. www.diariodesalud.com.do · www.azolifesciences.com · science20.com · www.globenewswire.com · conowego.pl
- [● 5 SOURCES] The study describing PROTEXI was published in Nature Communications on 27 July 2026. science20.com · www.diariodesalud.com.do · conowego.pl · www.azolifesciences.com · www.globenewswire.com
- [● 5 SOURCES] PROTEXI showed effectiveness in humanized mouse models using immune cells from COVID‑19‑vaccinated donors. www.azolifesciences.com · www.diariodesalud.com.do · conowego.pl · science20.com · www.globenewswire.com
- [● 5 SOURCES] Researchers plan to begin first‑in‑human clinical trials of PROTEXI in sarcoma patients. www.diariodesalud.com.do · science20.com · conowego.pl · www.azolifesciences.com · www.globenewswire.com
- [● 5 SOURCES] PROTEXI transformed immune‑cold tumors into ones recognizable by the immune system. www.diariodesalud.com.do · www.azolifesciences.com · science20.com · conowego.pl · www.globenewswire.com
- [● 2 SOURCES] PROTEXI generated durable antitumor memory and enhanced CD8+ T‑cell responses via CD4+ helper T‑cell memory. www.azolifesciences.com · science20.com
- [● 4 SOURCES] PROTEXI uses SARS‑CoV‑2 Spike protein epitopes to boost CD4+ helper T‑cell immunity and enhance CD8+ cytotoxic T‑cell anti‑tumor responses. www.diariodesalud.com.do · www.azolifesciences.com · science20.com · conowego.pl
- [● 5 SOURCES] PROTEXI improved survival in preclinical mouse models of melanoma and breast cancer. www.diariodesalud.com.do · www.azolifesciences.com · science20.com · www.globenewswire.com · conowego.pl
- [● 2 SOURCES] The research on PROTEXI was published in Nature Communications on 27 July 2026. www.diariodesalud.com.do · science20.com